Integrating AI with RWE to Accelerate Path to Market

The most recent FDA reauthorization legislation continues to support thoughtful expansion of real-world evidence (RWE) in new drug approval decision-making.  Leading companies are applying artificial intelligence algorithms to find the most relevant evidence amid mountains of real-world, clinical data to identify the patient subgroups and best biomarkers of indications to speed novel drug development, saving money and time versus traditional approaches.  A panel of experts will share their experiences and advice for applying AI to RWE to improve drug development program productivity.